Vaccines

Year in Review 2022: Achievements, milestones abounded during the past year

The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2022.

VUMC in the news, Nov. 22, 2022

Several from VUMC among most highly cited researchers

Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

Study finds Moderna’s COVID-19 vaccine safe and effective for young children

A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

Pending COVID-19 samples are prepared for testing in the Diagnostic Laboratories at VUMC.

Event to spotlight VUMC’s COVID-19 research efforts

The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.

1 2 3 4 5 14